Medicinal & Aromatic Plants
Strategy Roadmap
Selvese Botanica is not positioned as a raw agricultural volume play. It is being built as an analytically verified botanical processing platform with contract farming, standardized extracts, essential oils and export-grade delivery discipline at its core.
Core Thesis
Multi-product resilience
The revenue base is not concentrated in a single crop. Essential oils, standardized extracts, hydrosols and industrial derivatives sit on the same platform.
Analytical moat
GC-MS, HPLC and lot verification are not support functions. They are the mechanism through which price premiums become defensible.
Disciplined scale-up
Facility investments are phased. The company scales market credibility and grower coordination before overextending fixed capital.
EU-led market entry
Europe is the first credibility market. The US and Gulf are treated as follow-on value layers rather than the initial proving ground.
How The Platform Works
The operating model combines a central analytical and processing hub with contract growing, phased capex and export-oriented commercialization.
Seedling & Agronomy
Seedlings, cultivation know-how and crop discipline move through a coordinated grower network rather than fragmented spot procurement.
Contract Farming Network
The scale logic sits in the grower network. This keeps expansion lighter on capital while improving supply security and farmer alignment.
Processing Backbone
Distillation, extraction, storage, packaging and quality control are structured around a central processing and analytical backbone.
Commercial Layer
The sales logic prioritizes export credibility, repeatability and quality-backed pricing over opportunistic volume at weak margins.
Portfolio Architecture
Essential Oils
High-value aromatic products with export relevance, especially where chemotype verification supports premium pricing.
Standardized Extracts
The second revenue pillar, reducing reliance on spot oil pricing and improving portfolio defensibility.
Hydrosols
A smaller but complementary revenue stream, best treated as a value-added co-product rather than the center of the model.
Industrial Derivatives
Longer-term circularity plays such as activated carbon are treated as roadmap extensions, not core model assumptions.
Market Entry Sequence
Europe first
Europe serves as the first pricing and credibility market. It is where quality language, documentation discipline and repeatable delivery are first validated.
United States extension
Once pricing credibility is established, the US becomes the next layer for premium positioning in cosmetics, wellness and ingredient channels.
Gulf premium layer
The Gulf market is treated as an additional premium layer rather than the first beachhead, allowing the company to enter with stronger positioning.
Key Financial Signals
Annual Financial Projection
| Line Item | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 |
|---|
Revenue, EBITDA and Net Profit Trajectory
2031 Revenue Mix and Capital Roadmap
Central facility setup
Initial facility and infrastructure investment for production, lab capability and site readiness.
Analytical and extraction backbone
Core capex for extraction, analytical capability, storage and export-readiness.
Expansion phases
Additional roadmap capex for capacity uplift and activated carbon remain expansion options beyond the base case.
Cash Flow Interpretation
Investment period
No meaningful commercial revenue yet. Capex and setup costs dominate the profile.
First commercial year
The model enters its first full commercial layer, but remains negative as the platform is still absorbing setup intensity.
Scale-up year
Revenue and annual profitability improve materially, but cumulative cash remains negative at year-end.
Break-even and maturity
The cumulative curve turns positive in 2030, with 2031 reflecting the mature base-case profile.
Risks The Model Explicitly Acknowledges
Commodity-style price pressure
The response is not volume chasing. It is portfolio balance, stronger extract economics and analytical differentiation.
Overbuilding too early
The phased capital logic is specifically designed to avoid aggressive debt-led expansion before the commercial base is proven.
Supply inconsistency
The contract grower model, lot control and central lab structure are intended to reduce quality drift and raw material instability.